News
Travere Therapeutics will host a conference call and webcast today, Thursday, September 5, 2024 at 6 p.m. ET to discuss the FDA full approval of FILSPARI.
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate ...
Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 16, Leerink Partners analyst Joseph Schwartz reiterated the firm’s ...
Travere Therapeutics stock suffered a bit of a setback last week as the FDA moved back the anticipated decision date on a recently submitted sNDA. Learn more on TVTX stock here.
Hosted on MSN10mon
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug - MSNTravere’s shares were up nearly 11% on Friday after the announcement. Investors were impressed with Filspari’s label expansion as it expanded the drug’s total addressable patient population.
SAN DIEGO — Travere Therapeutics, a biotech focused on treating rare diseases, on Monday announced that a Phase 3 trial of an experimental treatment for focal segmental glomerulosclerosis, a ...
Travere Therapeutics: Tanking On Confirmatory Trial Failure For Kidney Therapy - Is There Hope? Sep. 22, 2023 7:30 AM ET Travere Therapeutics, Inc. (TVTX) Stock TVTX 4 Comments 2 Likes Edmund ...
--Travere Therapeutics, Inc., today announced that the U.S. Food and Drug Administration has granted full approval to FILSPARI ® to slow kidney function decline in adults with primary IgAN who ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results